Co-prescription of opioid and benzodiazepine products increases the risk of overdose-related mortality four-fold due to respiratory depression. Accordingly, prevention of high-risk opioid prescribing (HROP) has become a focus over the past two decades and was the subject of a black-box warning (BBW) issued by the U.S. Food and Drug Administration (FDA) on August 31, 2016. Because older patients are at increased risk for these outcomes, we compared rates of HROP for older (aged ≥65 years) and younger (aged 18-64 years) adults using a repeated cross-sectional cohort design. Data from the National Ambulatory Medical Care Survey of U.S. office-based physician visits were accessed for 2006-2016 August. From 2006 to 2016, the opioid-prescribing rate increased by 40% among those aged 18-64 years and by 54% among those aged ≥65 years. From 2012-2013 to 2014-2016, the HROP rate, expressed as a proportion of all opioid-prescribing visits, increased to 26.6% among those aged 18-64 years but declined to 21.0% among those aged ≥65 years, primarily because of changes for patients aged ≥75 years. Prior to the FDA-issued BBW, the HROP prescribing rate trended upward for all adults, except in 2014-2016 when it began to decline among older adults.
Introduction
Prevention of opioid overdose-related mortality has become a key target of public health promotion in the past two decades due to rapid increases in use and misuse of both prescribed and/or illicit opioids (Centers for Disease Control and Prevention, 2018; Guy et al., 2017; Kanouse and Compton, 2015) . The rate of opioid overdose-related mortality increases up to 4-fold with co-prescribed benzodiazepines, primarily because the risk of respiratory depression, which is independently associated with each medication, is compounded when the two are co-administered (Jones and McAninch, 2015; Park et al., 2015; Sun et al., 2017) . Given this risk, on August 31, 2016, the U.S. Food and Drug Administration (FDA) announced requirements for a "black box" warning. This warning is included in the prescribing information for all benzodiazepine-or opioid-containing products to alert prescribers of the serious risk of respiratory depression and death from opioid-benzodiazepine co-prescription. The warning suggests prescribing this combination only if necessary, for a limited duration, at a limited dose, only if alternative treatment options are unavailable, and with close monitoring (U.S. Food and Drug Administration, 2016) .
Even before the FDA warning was issued, trends in opioid-benzodiazepine co-prescription may have begun to decline, but evidence on this point is inconsistent. One analysis of office visits made by adults aged ≥20 years for pain-related conditions found that the rate of opioid co-prescription in patients using benzodiazepines, measured per 1000 persons, increased by 86% from 189 in 2005 to 351 in 2010, and declined thereafter to 172 in 2015 (Ladapo et al., 2018) . However, another study using the same data source and measuring opioid-benzodiazepine co-prescription in adults aged 18-64 years making an office visit for pain-related conditions found a relatively steady rate of increase from 9.8 per 10,000 visits in 1993 to 62.5 per 10,000 visits in 2014 (Hirschtritt et al., 2018) .
Whether this difference in findings reflects the inclusion of older adults in the study by Ladapo et al. but not that of Hirschtritt et al. is an important question, because the morbidity and mortality risks associated with opioid-benzodiazepine co-prescription are elevated in patients aged ≥65 years. In one study of emergency visits made for coprescribed opioid-benzodiazepine from 2005 to 2011, patients aged ≥65 years had the highest predicted risk of hospital admission or death compared with patients in younger age groups (Substance Abuse and Mental Health Services Administration, 2014). Opioid-benzodiazepine combined misuse also increases the risk of suicidal ideation in older adults . Because of these risks, the generally limited base of evidence about the prevalence and predictors of opioidbenzodiazepine misuse by older adults has been identified as an important gap in the literature (Maree et al., 2016) , and our more recent search of the literature on medication use by older adults supports this viewpoint (Hirschtritt et al., 2018; Ladapo et al., 2018) .
In addition to addressing this gap in information about older adults, the present study was conducted to expand the surveillance of high-risk opioid prescribing (HROP) in two ways. First, the study included barbiturates and hypnotics in the definition of HROP because opioid-related respiratory depression risk may be increased by central nervous system depressants other than benzodiazepines (Paulozzi et al., 2012; National Institute on Drug Abuse, 2018) . Second, all opioid-treated patients, rather than only those with pain-related diagnoses, were included in the present study sample to inform prevention initiatives by providing information about population-level prevalence and predictors of HROP. The study examined trends in opioid and HROP over the ten-year period beginning in 2006, comparing rates of use in cohorts of patients aged 18-64 years and ≥65 years. Additionally, the study assessed predictors of HROP in 2014 through the first 8 months of 2016, the 32-month time period preceding the FDA black-box warning.
Materials and methods

Data source
Study data were obtained from the National Ambulatory Medical Care Survey (NAMCS), a nationally representative assessment of care provided in office visits made to non-federally employed U.S. physicians, which is conducted annually by the National Center for Health Statistics (NCHS). NAMCS data are widely used in published research on use of medications, including controlled substances (Hirschtritt et al., 2018; Fairman et al., 2017; Gerlach et al., 2017; Olfson et al., 2013) .
Details of the NAMCS sampling strategy and data collection methods are described in detail elsewhere (National Center for Health Statistics, 2015a). Briefly, the NCHS uses a complex, multistage sampling design that includes stratification by physician specialty, cluster sampling by physician, random selection of one of 52 weeks each year, and random sampling of visits within the chosen week. Prior to 2012, cluster sampling by geographic area was also employed. For each sampled office visit, U.S. Bureau of the Census field representatives abstract data elements from the medical record using an automated laptop-based survey instrument (National Center for Health Statistics, 2015b) .
Data collected by the NCHS include diagnoses (up to three until 2013, up to five beginning in 2014); treatments, services, and laboratory tests ordered or provided at the visit; and prescribed medications that were either initiated or continued by the treating provider. Although up to 30 drugs are currently recorded in NAMCS, the present study is based on the first eight listed drugs through 2011, the maximum recorded in that time frame, and the first ten listed drugs thereafter. Additionally, data collectors record conditions that are clinically important but may not have prompted the extant office visit. Examples include diabetes, hypertension, and hyperlipidemia.
Design and sample
Choice of the design, sample, and analytic covariates for the present study were based on a review of the literature on use of opioids and other controlled substances by older adults. We used a repeated crosssectional cohort design in which office visits were the unit of analysis. The sampling frame comprised all office visits provided to U.S. adults aged 18 years or older on the visit date during the period from 2006 through the first 8 months of 2016. Cohorts were defined based on age:
18-64 years and ≥65 years. To provide additional information about utilization patterns by age group, especially for older adults, age categories for post hoc analyses of time trends and for logistic regression analyses were based on those of Hirschtritt et al. (2018) , with added categories representing adults aged 65-74 and ≥75 years. Another post hoc trend analysis examined trends for patients with chronic noncancer pain or substance use disorder because opioid use in these groups has been a target of public health initiatives (Dowell et al., 2016) .
Study measures
To identify drugs for study, Multum Lexicon generic drug codes provided by the NCHS were matched to drug names, which were classified into therapy categories for analysis (Appendix 1). Drug-related measures included the prescribing of at least one opioid at the visit, alone or with a barbiturate, benzodiazepine, or hypnotic (i.e., HROP). Medical conditions and comorbidities were identified using condition/comorbidity indicators and diagnoses, measured as International Classification of Diseases, Ninth Revision (ICD-9) codes in 2014-2015 and ICD-10 codes in 2016 (Appendix 2).
Statistical analyses
Use prevalence rates for each drug or drug combination were defined as the number of visits at which the drug was newly prescribed or continued, divided by the total number of visits. HROP prevalence rates were calculated as total number of HROP visits expressed as a proportion of all visits at which an opioid was prescribed. Longitudinal analysis examined these rates over time, grouping data into multiyear time periods as advised by the NCHS to increase statistical reliability, a commonly used technique in analyses of this dataset (Fairman et al., 2017; Hsiao, 2010; Myrick, n.d.; Olfson et al., 2013) .
For the most recent time period included in the study, 2014 through the first 8 months of 2016, patient characteristics-including sex, cardiovascular risk factors and diagnosed cardiovascular disease, chronic pain, psychiatric conditions, and substance use disorder-were measured as prevalence rates (total number of visits in which the diagnosis or condition was reported, divided by total number of visits). In bivariate analyses of high-risk opioid users, these calculations were performed separately for each of the two age groups. Characteristics included in these analyses were chosen from literature review, specifically based on (a) those reported by Hirschtritt et al. as significant predictors of opioid-benzodiazepine use compared with opioid use alone, such as substance use disorder, anxiety, and depression, plus (b) risk factors (e.g., diabetes, hypertension) and diagnoses for cardiovascular or respiratory diseases, which are often chronically comorbid with substance use disorders (Wu et al., 2018) .
To assess the independent associations of each demographic and clinical characteristic with high-risk opioid use, a binary logistic regression of high-risk opioid use on demographic and clinical predictors was performed. To increase statistical power for this analysis, the list of cardiovascular risk factors was recoded to categories of 1, 2, or ≥3, compared with no (0) risk factors as the reference category. Additionally, predictors that were insignificant in both the work of Hirschtritt et al. (2018) and in the bivariate analysis were not included in the logistic regression analysis, with the exception that chronic pain was included because of the focus on patients with this condition in previous work (Hirschtritt et al., 2018; Ladapo et al., 2018) . The logistic regression analysis was limited to patients without cancer due to the high rate of opioid use within this population.
Statistical reliability and calculation of nationally representative estimates
For each office visit record, the NCHS provides (1) a weight that adjusts for the sampling design and nonresponse and (2) sample design weights that reflect the clustered and stratified design. Using these weights, procedures for complex samples produce nationally representative estimates and sampling variance measures that have been adjusted for sampling design. For the present study, the SPSS (IBM SPSS, Armonk, NY) v25.0 complex samples procedure was used. Estimates were assessed for statistical reliability using the standard recommended by the NCHS of ≥30 records and ratio of standard error to the estimate < 30% (National Center for Health Statistics, 2015b). 2006 to 2007 to 2014-2016 August, opioid prescribing rates in office visits made by adults increased by 40% (from 9.2% to 12.9%) among those aged 18-64 years and by 54% (from 7.1% to 10.9%) among those aged ≥65 years ( Fig. 1 ). For both age groups, about onefifth of visits in which opioids were prescribed in 2006-2007 included a concomitant high-risk drug (barbiturate, benzodiazepine, or hypnotic).
Results
From
Through 2012-2013, both age groups displayed similar patterns of increase in HROP rates, expressed as a proportion of opioid-prescribing visits. In 2014-2016 August, HROP rates continued to increase to 26.6% among those aged 18-64 years, while declining to 21.0% among those aged ≥65 years, resulting in a very slight decline from 24.8% in 2012-2013 to 24.6% in 2014-2016 for adults overall (results for all adults not shown in Fig. 1) .
A post-hoc analysis with separate trends for those aged 50-64 years, 65-74 years, and ≥75 years showed a decline in opioid use by those aged ≥75 years (Fig. 2, Panel A) and a leveling off of HROP among patients aged 65-74 years who were prescribed opioids, from 22.9% in 2012-2013 to 22.7% in 2014-2016 August (Fig. 2, Panel B) . Among patients aged ≥75 years who were prescribed opioids, trends in HROP fluctuated over time, declining to 18.5% in 2014-2016 August (Fig. 2,  Panel B) . Sensitivity analyses of patients with chronic noncancer pain or substance use disorder produced similar results, although the number of older adults with substance use disorder was insufficient for analysis (Table 1) . In these visits, commonly recorded diagnoses or conditions included chronic pain (50%), hypertension (42%), and depression (25%).
As expected, rates of cardiovascular risk factors were significantly higher for older than younger adults; and 28% of older adults, compared with 7% of younger adults, had a diagnosis of cardiovascular disease. Conversely, younger adults were more likely than older adults to have a diagnosis of chronic pain (52% vs. 44%, respectively), depression (27% vs. 20%), or substance use disorder (14% vs. 5%, respectively), and were much more likely to use tobacco (38% vs. 20%, respectively). Anxiety was also common among younger adults (18%). In bivariate analysis of predictors, these factors were strongly predictive of high-risk opioid use, as were age categories based on the work of Hirschtritt et al. (2018) (Appendix 4) .
In the logistic regression analysis, the odds of HROP were multiplied by 3.67 (95% confidence interval [CI] = 2.91-4.64) with a diagnosis of chronic pain; by 3.52 (95% CI = 2.29-5.41) with anxiety; and were more than doubled with current tobacco use or substance use disorder (Table 2) . Cardiovascular risk factors were also associated with increased odds of HROP, although to a lesser degree. Compared with the reference group of adults aged 35-49 years, odds of HROP were not significantly different among those 50-64 years or 65-74 years, but were significantly lower for those aged 18-34 years (odds ratio = 0.53, 95% CI = 0.38-0.74) and those aged ≥75 years (odds ratio = 0.55, 95% CI = 0.36-0.84).
Discussion
In physician office visits made by patients aged ≥65 years, the rate of HROP, which had increased steadily over time from 2006-2007 to 2012-2013 , began to decline in 2014-2016 August, primarily because of changes occurring among patients aged ≥75 years and a leveling of A.M. Peckham, et al. Preventive Medicine Reports 15 (2019) 100892 the HROP rate among those aged 65-74 years. Since previous research has found a strong association between use of high-risk opioid combinations and high direct and indirect costs, the decreased rate of HROP may translate to improved patient outcomes, decreased costs, and prevention of opioid-overdose related mortality (Reinhart et al., 2018; Kacara-Mandic et al., 2017) . Although a positive finding because of the elevated risk of respiratory depression in older adults, this result is surprising because our study period preceded the issuance of the new FDA guidance on opioidbenzodiazepine co-prescription. The decline in prescribing rates may have been due to several states implementing more stringent requirements for opioid prescriptions prior to 2016. It is also possible that concern about potential opioid-related risks for the "older-older" has increased (Jaul and Barron, 2017) . Our findings are consistent with those of a previous study that reported reduced high-dose opioid use with age ≥75 years (Musich et al., 2019) , perhaps because known opioid-related risks, such as cardiovascular events or fractures (Saunders et al., 2010; Solomon et al., 2010) are highly prevalent and clinically serious in this age group (Jaul and Barron, 2017) .
In contrast to the findings for older adults, the rate of HROP in patients aged 18-64 years continued to increase in 2014-2016 August. The rate of HROP was multiplied > 3-fold with diagnoses of either chronic pain or anxiety, and doubled with a diagnosis of tobacco or substance use disorder. The continued increase of HROP overlaid with these diagnoses may result in unintended harm, such as increased risk of opioid-overdose related mortality.
Among all study patients, there was a slight decline in HROP from 2012-2013 to 2014-2016 . This finding aligns with that of Ladapo et al. (2018) , who found an overall reduction in HROP prevalence over time. This reduction was not apparent in the study by Hirschtritt et al. (2018) , likely due to the exclusion of patients aged ≥65 years from their sample. Despite the present study's finding of improvement in HROP rates among patients aged ≥65 years, it should be noted that rates for both age groups remain elevated above those from 2006 to 2007. Additionally, despite the decline in HROP rates, rates of opioid prescribing overall continued to increase among older adults from 2012-2013 to 2014-2016 August, highlighting the importance of public health prevention strategies for opioid use reduction. In concert with the recommendations of the FDA, the Centers for Disease Control and Prevention (CDC) released Guidelines for Prescribing Opioids for Chronic Pain in 2016 that suggest non-pharmacological and non-opioid treatment modalities when managing chronic pain (U.S. Food and Drug Administration, 2016; Dowell et al., 2016) . As interest in the risks associated with increased controlled substance use and misuse by older adults continues to grow (Han et al., 2019; Huang et al., 2018; McCabe et al., 2019) , continued monitoring of trends in HROP in this age group is warranted. Additional research to clarify sociocultural predictors of high-risk drug use, such as family history, criminality, or socioeconomic status, may be helpful to providers who wish to identify older adults who are at elevated risk (Ranapurwala et al., 2018; Webster, 2017) .
Limitations
Several limitations of the study should be noted. First, the NAMCS does not measure medication strength, prescribed duration or dosage, or patient adherence. Second, each NAMCS record represents a single physician office visit. Other than the medical condition codes (e.g., hypertension, diabetes), the NAMCS record does not provide information on patient history. Third, although the NAMCS record does include medications prescribed by another physician and continued by the sampled physician, it does not capture illicit drugs, prescriptions intentionally concealed by patients (e.g., in "doctor shopping"), or medication that was discontinued in the sampled office visit. Fourth, the study sample represents care delivered in physician office visits, not in emergency departments or inpatient hospital settings.
Conclusion
While prescribing rates of high-risk opioid use declined in older adults prior to the FDA Black Box Warning regarding opioid-benzodiazepine co-prescription, these rates continued to trend upwards through the first 8 months of 2016 in adults aged 18-64 years. Future studies are needed to assess the impact of the FDA Black Box Warning and CDC Chronic Pain Guideline from 2016 on the rates of HROP.
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